Company Encyclopedia
View More
name
Lexicon Pharma
LXRX.US
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc.
4.514 T
LXRX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking74/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-45.92%E
    • Profit Margin-96.77%E
    • Gross Margin-32.33%E
  • Growth ScoreB
    • Revenue YoY1255.21%A
    • Net Profit YoY68.31%A
    • Total Assets YoY-35.87%E
    • Net Assets YoY-32.69%E
  • Cash ScoreB
    • Cash Flow Margin-103.33%D
    • OCF YoY1255.21%A
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreC
    • Gearing Ratio41.65%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences

    Lexicon Pharmaceuticals Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 3 and the 8th Annual Evercore Healthcare Conference on December 4. The company will host a fireside chat and presentations, which will be available live and as replays on their website. This information was originally published by Lexicon Pharmaceuticals via GlobeNewswire.

    Reuters·
    US
    LXRX
    +1.43%
    Reuters·
    US
    LXRX
    +1.43%

    Lexicon Pharmaceuticals to Join Jefferies London Healthcare Conference

    Lexicon Pharmaceuticals Inc. will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18, 2025. The event will be accessible via the company's website. This announcement was originally published on GlobeNewswire on November 11, 2025.

    Reuters·
    US
    LXRX
    +1.43%
    Reuters·
    US
    LXRX
    +1.43%

    Promising Potential of Lexicon Pharmaceuticals’ Sotagliflozin in Cardiometabolic Treatments: Analyst Recommends Buy Rating

    Analyst Joseph Pantginis from H.C. Wainwright has maintained a Buy rating on Lexicon Pharmaceuticals, with a price target of $4.00. This recommendation is based on the promising potential of sotagliflozin in treating cardiometabolic conditions, particularly highlighted by the ongoing Phase 3 SONATA-HCM trial. The drug shows efficacy in addressing adverse cardiac remodeling and has demonstrated significant reductions in major adverse cardiovascular events. Citi also reiterated a Buy rating with a $1.90 price target.

    Tip Ranks·
    US
    LXRX
    +1.43%
    Tip Ranks·
    US
    LXRX
    +1.43%

    Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes

    Lexicon Pharmaceuticals Inc. announced new clinical data showing that sotagliflozin improves outcomes in heart failure with preserved ejection fraction (HFpEF) patients without diabetes. Presented at the AHA Annual Scientific Sessions 2025, the study involved 88 participants and demonstrated significant improvements in left ventricular mass, diastolic function, and KCCQ scores over six months. This is the first study to show clinical benefits of sotagliflozin for HFpEF patients without diabetes.

    Reuters·
    US
    LXRX
    +1.43%
    Reuters·
    US
    LXRX
    +1.43%

    Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 | LXRX Stock News

    Lexicon Pharmaceuticals presented new clinical data on sotagliflozin at the AHA Annual Scientific Sessions 2025, highlighting its efficacy in improving cardiac performance and quality of life in heart failure patients with preserved ejection fraction (HFpEF) without diabetes. The study, led by Dr. Juan J Badimon, involved 88 participants and showed significant improvements in cardiac structure, function, and functional capacity after six months of treatment. Sotagliflozin, an oral inhibitor of SGLT2 and SGLT1, is also being investigated for other cardiac conditions. Lexicon aims to pioneer innovative medicines through its genomics target discovery platform.

    StockTitan·
    US
    LXRX
    +1.43%
    StockTitan·
    US
    LXRX
    +1.43%
    © 2025 Longbridge｜Disclaimer